Michael Best & Friedrich LLP
Therapeutic use of agonist ligands specific to G2A receptor
The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.
Biosynergen, Inc.
A A A A A A A A Y A A A A A A A A A A A A
A61P A61P A61P A61P A61P A61P A61P A61K Y02A A61P A61P A61P A61P A61P A61P A61P A61K A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Sung-Oh Hong-Won Yung-Hi Dong-Keun
Huh Suh Kim Song